TWD 5.04
(-1.95%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 5.95 Million USD | 4.87% |
2022 | 29.1 Million USD | 14.92% |
2021 | 25.32 Million USD | -28.01% |
2020 | 35.17 Million USD | 369.28% |
2019 | 7.49 Million USD | -2.14% |
2018 | 7.66 Million USD | 6.23% |
2017 | 7.21 Million USD | 10.21% |
2016 | 6.54 Million USD | -3.01% |
2015 | 6.74 Million USD | 10.57% |
2014 | 6.1 Million USD | -10.71% |
2013 | 6.83 Million USD | -5.26% |
2012 | 7.21 Million USD | -5.44% |
2011 | 7.62 Million USD | -14.32% |
2010 | 8.9 Million USD | -7.91% |
2009 | 9.66 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 9.3 Million USD | -52.77% |
2023 FY | 30.51 Million USD | 4.87% |
2023 Q2 | 10.3 Million USD | -29.64% |
2023 Q4 | 19.71 Million USD | 91.36% |
2022 Q2 | 12.76 Million USD | -9.63% |
2022 FY | 29.1 Million USD | 14.92% |
2022 Q4 | 14.63 Million USD | 14.69% |
2021 Q4 | 14.12 Million USD | 21.59% |
2021 Q2 | 11.61 Million USD | -57.82% |
2021 FY | 25.32 Million USD | -28.01% |
2020 Q2 | 7.58 Million USD | 145.45% |
2020 Q4 | 27.53 Million USD | 262.96% |
2020 FY | 35.17 Million USD | 369.28% |
2019 Q4 | 3.09 Million USD | -19.61% |
2019 Q2 | 3.84 Million USD | 4.63% |
2019 FY | 7.49 Million USD | -2.14% |
2018 Q4 | 3.67 Million USD | -1.66% |
2018 FY | 7.66 Million USD | 6.23% |
2018 Q2 | 3.73 Million USD | 7.69% |
2017 Q4 | 3.46 Million USD | -9.23% |
2017 Q2 | 3.82 Million USD | 36.68% |
2017 FY | 7.21 Million USD | 10.21% |
2016 FY | 6.54 Million USD | -3.01% |
2016 Q4 | 2.79 Million USD | -19.23% |
2016 Q2 | 3.46 Million USD | -0.4% |
2015 FY | 6.74 Million USD | 10.57% |
2015 Q4 | 3.47 Million USD | 9.2% |
2015 Q2 | 3.18 Million USD | 28.39% |
2014 Q2 | 3.25 Million USD | -5.6% |
2014 FY | 6.1 Million USD | -10.71% |
2014 Q4 | 2.48 Million USD | -23.72% |
2013 Q4 | 3.44 Million USD | -4.04% |
2013 FY | 6.83 Million USD | -5.26% |
2013 Q2 | 3.58 Million USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | 7.21 Million USD | -5.44% |
2011 Q2 | - USD | 0.0% |
2011 FY | 7.62 Million USD | -14.32% |
2011 Q4 | - USD | 0.0% |
2010 FY | 8.9 Million USD | -7.91% |
2010 Q4 | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 FY | 9.66 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 495.65 Million TWD | 98.798% |
Maxigen Biotech Inc. | 274.24 Million TWD | 97.828% |
SciVision Biotech Inc. | 312.85 Million TWD | 98.096% |
Bionime Corporation | 673.63 Million TWD | 99.116% |
Pegavision Corporation | 1.68 Billion TWD | 99.647% |
Visco Vision Inc. | 522.44 Million TWD | 98.86% |